CL2014001247A1 - Solid dosage form for immediate release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide; Preparation method. - Google Patents

Solid dosage form for immediate release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide; Preparation method.

Info

Publication number
CL2014001247A1
CL2014001247A1 CL2014001247A CL2014001247A CL2014001247A1 CL 2014001247 A1 CL2014001247 A1 CL 2014001247A1 CL 2014001247 A CL2014001247 A CL 2014001247A CL 2014001247 A CL2014001247 A CL 2014001247A CL 2014001247 A1 CL2014001247 A1 CL 2014001247A1
Authority
CL
Chile
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
trifluoro
Prior art date
Application number
CL2014001247A
Other languages
Spanish (es)
Inventor
Upkar Bhardwaj
Mangesh Sadashlv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014001247A1 publication Critical patent/CL2014001247A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
CL2014001247A 2011-11-14 2014-05-13 Solid dosage form for immediate release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide; Preparation method. CL2014001247A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
CL2014001247A1 true CL2014001247A1 (en) 2014-10-17

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001247A CL2014001247A1 (en) 2011-11-14 2014-05-13 Solid dosage form for immediate release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide; Preparation method.

Country Status (22)

Country Link
EP (1) EP2779995A1 (en)
JP (1) JP6275645B2 (en)
KR (1) KR20140093230A (en)
CN (1) CN103930094A (en)
AR (1) AR088844A1 (en)
BR (1) BR112014011518A2 (en)
CA (1) CA2855503A1 (en)
CL (1) CL2014001247A1 (en)
CO (1) CO6960546A2 (en)
EA (1) EA201490960A1 (en)
GT (1) GT201400094A (en)
HK (1) HK1197025A1 (en)
IL (1) IL232480A0 (en)
IN (1) IN2014DN03416A (en)
MA (1) MA35636B1 (en)
MX (1) MX2014005874A (en)
PE (1) PE20141337A1 (en)
SG (2) SG11201401476TA (en)
TN (1) TN2014000177A1 (en)
TW (1) TWI574690B (en)
WO (1) WO2013074432A1 (en)
ZA (1) ZA201402756B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (en) 2017-12-20 2019-07-03 Zentiva, K.S. Dosing of crystalline nilotinib
JP7378279B2 (en) 2019-11-18 2023-11-13 日本化薬株式会社 Pharmaceutical tablet containing nilotinib as an active ingredient and method for producing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (en) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
WO2013074432A1 (en) 2013-05-23
MX2014005874A (en) 2014-06-23
TN2014000177A1 (en) 2015-09-30
MA35636B1 (en) 2014-11-01
CO6960546A2 (en) 2014-05-30
EA201490960A1 (en) 2014-08-29
ZA201402756B (en) 2015-04-29
TWI574690B (en) 2017-03-21
AU2012339829A1 (en) 2014-05-29
KR20140093230A (en) 2014-07-25
JP6275645B2 (en) 2018-02-07
GT201400094A (en) 2017-09-28
HK1197025A1 (en) 2015-01-02
NZ623844A (en) 2016-09-30
IL232480A0 (en) 2014-06-30
CA2855503A1 (en) 2013-05-23
TW201325594A (en) 2013-07-01
BR112014011518A2 (en) 2017-05-16
IN2014DN03416A (en) 2015-06-26
SG10201707768RA (en) 2017-10-30
JP2014533283A (en) 2014-12-11
EP2779995A1 (en) 2014-09-24
AR088844A1 (en) 2014-07-10
SG11201401476TA (en) 2014-10-30
CN103930094A (en) 2014-07-16
AU2012339829B2 (en) 2016-05-12
PE20141337A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
CO6801777A2 (en) Modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro -methyl) -phenyl] -benzamide solubilized using organic acids
HK1217487A1 (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction -2 n-[4-(2--12---4- )-]-
IL279910A (en) Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2- {2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
IL236495A0 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk)inhibitors
DK2878598T3 (en) Crystalline Form of 4- [5- (PYRIDIN-4-YL) -1H-1,2,4-TRIAZOL-3-YL] PYRIDIN-2-CARBONITRIL
EP2694486A4 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
IL232059B (en) Use of inhibitors of bruton's tyrosine kinase (btk)
CO6811863A2 (en) Compounds of 2- (2,4,5-substituted anilino) pyrimidine
PE20121476A1 (en) COMPOSITION FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY THE KINASE ACTIVITY OF BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R
SI2632921T1 (en) Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-((4-(1-methylethyl)-1-piperazinyl)methyl)-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof
SI3077390T1 (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
CL2014001247A1 (en) Solid dosage form for immediate release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide; Preparation method.
IL231958B (en) Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2- trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
SG11201604517WA (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
PT2943488T (en) Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors
BR112013025679A2 (en) protein kinase inhibitors of new indolinone compounds
PL395738A1 (en) New medical use for 4- (n-butyl) -5- (3-chlorophenyl) -2,4-dihydro-3H-1,2,4-triazole-3-thione
TH132151A (en) ((R) - (E) -2- (4- (2- (5- (1- (3,5-dichloropyridin-4-il) ethoxy) -1H-in Dasol-3-il) vinyl) -1H-pyrazol-1-il) crystalline ethanol